Maze Therapeutics Inc Forecast, price target & analysts
Maze Therapeutics Inc Target price 2026 - Analyst rating & recommendation
Maze Therapeutics Inc Classifications & Recommendation
Maze Therapeutics Inc Price Target
| Target Price | $56.61 |
| Price | $26.43 |
| Potential |
114.19%
register free of charge
|
| Number of Estimates | 13 |
|
13 Analysts have issued a price target Maze Therapeutics Inc 2027 .
The average Maze Therapeutics Inc target price is $56.61.
This is
114.19%
register free of charge
$115.50
337.00%
register free of charge
$46.46
75.79%
register free of charge
|
|
| A rating was issued by 18 analysts: 17 Analysts recommend Maze Therapeutics Inc to buy, 1 to hold and 0 to sell. | |
| Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
|
Analyst Estimates: Analysts believe that the Maze Therapeutics Inc stock has an average upside potential 2027 of
114.19%
register free of charge
|
Sales and Margin forecast 2026, 2027 to 2033
| Dec '25 |
2026 Estimates |
|
|---|---|---|
| Revenue Million $ | 0.00 | 20.40 |
| 100.00% |
13 Analysts have issued a sales forecast Maze Therapeutics Inc 2026 . The average Maze Therapeutics Inc sales estimate is
This results in the following potential growth metrics:
3 Analysts have issued an Maze Therapeutics Inc EBITDA forecast 2026. The average Maze Therapeutics Inc EBITDA estimate is
This results in the following potential growth metrics and future EBITDA Margins:
13 Maze Therapeutics Inc Analysts have issued a net profit forecast 2026. The average Maze Therapeutics Inc net profit estimate is
This results in the following potential growth metrics and future Net Margins:
Earnings per share, P/E ratio and EV/sales Estimates 2026, 2027 to 2033
| Dec '25 |
2026 Estimates |
|
|---|---|---|
| Earnings Per Share $ | -3.05 | -2.89 |
| 3,912.50% | 5.25% | |
| P/E | negative | |
| EV/Sales | 53.73 |
13 Analysts have issued a Maze Therapeutics Inc forecast for earnings per share. The average Maze Therapeutics Inc EPS is
This results in the following potential growth metrics and future valuations:
Maze Therapeutics Inc...
Current Maze Therapeutics Inc Upgrades & Downgrades
| Analyst | Rating | Action | Date |
|---|---|---|---|
| HC Wainwright & Co. |
Locked
➜
Locked
|
Locked | Sep 24 2026 |
| Citigroup |
Locked
➜
Locked
|
Locked | Sep 23 2026 |
| Wedbush |
Locked
➜
Locked
|
Locked | Sep 23 2026 |
| BTIG |
Locked
➜
Locked
|
Locked | Sep 22 2026 |
| BTIG |
Locked
➜
Locked
|
Locked | Aug 12 2026 |
| Truist Securities |
Locked
➜
Locked
|
Locked | Apr 14 2026 |
| JP Morgan |
Locked
➜
Locked
|
Locked | Mar 31 2026 |
| Analyst Rating | Date |
|---|---|
|
Locked
HC Wainwright & Co.:
Locked
➜
Locked
|
Sep 24 2026 |
|
Locked
Citigroup:
Locked
➜
Locked
|
Sep 23 2026 |
|
Locked
Wedbush:
Locked
➜
Locked
|
Sep 23 2026 |
|
Locked
BTIG:
Locked
➜
Locked
|
Sep 22 2026 |
|
Locked
BTIG:
Locked
➜
Locked
|
Aug 12 2026 |
|
Locked
Truist Securities:
Locked
➜
Locked
|
Apr 14 2026 |
|
Locked
JP Morgan:
Locked
➜
Locked
|
Mar 31 2026 |
Discover more stocks with a high price target
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.
